AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
AxoGen (AXGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen (NASDAQ: AXGN) executives said a newly secured Biologics License Application (BLA) approval has preserved the company's ability to serve patients across a broad range of peripheral nerve repair needs, while also helping address remaining reimbursement and coverage barriers that have affected adoption. BLA label seen as broad, consistent with prior use CEO Mike Dale said
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen Q4: EPS Miss Amid Biologics Transition
Axogen, Inc. (AXGN) reported strong 21% revenue growth but missed EPS expectations, prompting an 8% share decline and highlighting near-term margin pressures. AXGN is transitioning to a regulated biologics platform with Avance FDA approval, aiming for sustainable growth, 18%+ revenue guidance, and positive free cash flow in 2026. Gross margin compression is driven by one-time regulatory costs and biologics conversion, expected to normalize as biologics pricing and payer coverage expand.
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
AxoGen (AXGN) came out with quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.08 per share a year ago.
Wasatch Micro Cap Fund Q4 2025 Performance Review
Leading individual contributors to the Fund's relative performance included Axogen, Inc., a holding within the health-care equipment industry. A provider of prepared food items such as meatballs and paninis, Mama's targets the deli area of grocery stores and warehouse clubs. On the downside, software distribution company Climb Global Solutions, Inc. was the Fund's leading laggard in the quarter.
